Matt, Author at European Medical Journal - Page 50 of 212

Continue
Doing More for Patients with Immune Thrombocytopenia
9 Mins
30 Jul 2020

Doing More for Patients with Immune Thrombocytopenia: Putting New Recommendations into Practice

The American Society of Hematology (ASH) guidelines and the International Consensus Report (ICR) recommendations were first published in 2010 and 2011…
hematology 8.1 featured image
2 Mins
30 Jul 2020

Gene Therapy For Fanconi Anaemia: A Report on Outcomes in Nine Patients

Fanconi anaemia (FA) is a rare, inherited bone marrow failure syndrome, for which the only available curative treatment is haematopoietic cell transplant…
hematology 8.1 featured image
10 Mins
30 Jul 2020

Outcomes for Patients with High-Risk Acute Myeloid Leukaemia: Can We Move from Months to Years?

This symposium focussed on the recognition of, and treatment options for, high-risk AML. Prof Cluzeau considered universal or targeted treatment…
AGILE: Phase III, Double-Blind, Randomised, Placebo-Controlled Study
2 Mins
30 Jul 2020

AGILE: Phase III, Double-Blind, Randomised, Placebo-Controlled Study of Ivosidenib in Combination with Azacitidine in Adults with Newly Diagnosed Acute Myeloid Leukaemia and an IDH1 Mutation

Isocitrate dehydrogenase 1 (IDH1) is a metabolic enzyme which catalyses the oxidative decarboxylation of isocitrate to α-ketoglutarate…
hematology 8.1 featured image
2 Mins
30 Jul 2020

Implementation of Haematological Malignancies Patient-Reported Outcome Measure in Clinical Practice: Haematologists’ Experience

Patients with haematological malignancies (HM) may experience significantly compromised quality of life (QoL) as a result of the disease and its…
hematology 8.1 featured image
2 Mins
30 Jul 2020

Integrative Analysis of the Genomic Landscape of Hodgkin Lymphoma Using Liquid Biopsies

The genomic landscape of Hodgkin lymphoma (HL) is not well understood because of the scarcity of Hodgkin-Reed–Sternberg cells, which makes conventional…
Phase Ib/II Study of the IDH1-Mutant Inhibitor Ivosidenib
3 Mins
30 Jul 2020

Phase Ib/II Study of the IDH1-Mutant Inhibitor Ivosidenib, with the BCL2-Inhibitor Venetoclax +/-Azacitidine in IDH1-Mutated Myeloid Malignancies

Venetoclax is a potent, selective, oral inhibitor of B-cell lymphoma-2. It is approved in the USA in combination with azacitidine, decitabine…
hematology 8.1 featured image
2 Mins
30 Jul 2020

Mechanistic Insights into the Inhibition of Regulatory T Cells by Dasatinib in Chronic Myeloid Leukaemia Patients with Clonal Lymphocytosis

Dasatinib is a potent inhibitor of lymphocyte-specific protein tyrosine kinase (Lck), which plays a pivotal role in T-cell receptor (TCR) signalling…
hematology 8.1 featured image
6 Mins
30 Jul 2020

Pregnancy-Related Thromboembolism in Sickle Cell Disease

Haematological disorders are predominant in the tropical and subtropical countries where major problems of sickle-cell disease (SCD) and thalassaemias…
hematology 8.1 featured image
2 Mins
30 Jul 2020

Identification of HIF2α as a Novel Determinant of Acute Myeloid Leukaemia Block of Differentiation Poses its Inhibition as a Potential Therapeutic Opportunity for Acute Myeloid Leukaemia Patients

Signalling via hypoxia inducible factors (HIF)1α and HIF2α is importantly implicated in cancer,1 although it has been predominantly studied in solid…
We’ve noticed you’re accessing
from North/South America.